title: Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
abstract: This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure.
  
  
  
  Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes.
  
  
  
  We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE.
  
  
  
  Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated.
  
  
  
  Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).
authors.affiliation: Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania. Electronic address: john.j.lepore@gsk.com.
authors.forename: John J
authors.initials: JJ
authors.lastname: Lepore
authors.affiliation: Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: Eric
authors.initials: E
authors.lastname: Olson
authors.affiliation: Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: Laura
authors.initials: L
authors.lastname: Demopoulos
authors.affiliation: Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: Thomas
authors.initials: T
authors.lastname: Haws
authors.affiliation: Quantitative Sciences, Clinical Statistics, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: Zixing
authors.initials: Z
authors.lastname: Fang
authors.affiliation: Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: April M
authors.initials: AM
authors.lastname: Barbour
authors.affiliation: Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania.
authors.forename: Michael
authors.initials: M
authors.lastname: Fossler
authors.affiliation: Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Victor G
authors.initials: VG
authors.lastname: Davila-Roman
authors.affiliation: Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
authors.forename: Stuart D
authors.initials: SD
authors.lastname: Russell
authors.affiliation: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Gropler
mesh_terms: D000328:Adult; D000368:Aged; D002250:Carbon Radioisotopes; D002908:Chronic Disease; D004452:Echocardiography; D017079:Exercise Tolerance; D005260:Female; D019788:Fluorodeoxyglucose F18; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D000072078:Positron Emission Tomography Computed Tomography; D011788:Quality of Life; D019275:Radiopharmaceuticals; D013318:Stroke Volume; D000070857:Walk Test
chemical_list: D002250:Carbon Radioisotopes; D054795:Incretins; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C534611:rGLP-1 protein; D052216:Glucagon-Like Peptide 1; D005947:Glucose
keywords: albiglutide; glucagon-like peptide-1 (GLP-1); heart failure